Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5 ′-triphosphate exposure to support posology for SARS-CoV-2

ConclusionsPopulation mean intracellular FAVI-RTP concentrations are estimated to be maintained above the Km for the SARS-CoV-2 polymerase for 9  days with a 1200 mg twice-daily regimen (following a 1600 mg twice-daily loading dose on day 1). Further evaluation of favipiravir as part of antiviral combinations for SARS-CoV-2 is warranted.
Source: Journal of Antimicrobial Chemotherapy - Category: Microbiology Source Type: research